Department of Surgery, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA.
J Neurooncol. 2012 Mar;107(1):155-64. doi: 10.1007/s11060-011-0722-2. Epub 2011 Oct 11.
We evaluated the efficacy of carboplatin, irinotecan, and bevacizumab among bevacizumab-naïve, recurrent glioblastoma (GBM) patients in a phase 2, open-label, single arm trial. Forty eligible patients received carboplatin (area under the plasma curve [AUC] 4 mg/ml-min) on day one, while bevacizumab (10 mg/kg) and irinotecan (340 mg/m(2) for patients on CYP3A-enzyme-inducing anti-epileptics [EIAEDs] and 125 mg/m(2) for patients not on EIAEDs) were administered on days 1 and 14 of every 28-day cycle. Patients were evaluated after each of the first two cycles and then after every other cycle. Treatment continued until progressive disease, unacceptable toxicity, non-compliance, or voluntary withdrawal. The primary endpoint was progression-free survival at 6 months (PFS-6) and secondary endpoints included safety and median overall survival (OS). All patients had progression after standard therapy. The median age was 51 years. Sixteen patients (40%) had a KPS of 90-100, while 27 (68%) were at first progression. The median time from original diagnosis was 11.4 months. The PFS-6 rate was 46.5% (95% CI: 30.4, 61.0%) and the median OS was 8.3 months [95% confidence interval (CI): 5.9, and 10.7 months]. Grade 4 events were primarily hematologic and included neutropenia and thrombocytopenia in 20 and 10%, respectively. The most common grade 3 events were neutropenia, thrombocytopenia, fatigue, and infection in 25, 20, 13, and 10%, respectively. Eleven patients (28%) discontinued study therapy due to toxicity and 17 patients (43%) required dose modification. One patient died due to treatment-related intestinal perforation. The addition of carboplatin and irinotecan to bevacizumab significantly increases toxicity but does not improve anti-tumor activity to that achieved historically with single-agent bevacizumab among bevacizumab-naïve, recurrent GBM patients. (ClinicalTrials.gov number NCT00953121).
我们在一项 2 期、开放标签、单臂试验中评估了卡铂、伊立替康和贝伐珠单抗在贝伐珠单抗初治复发性胶质母细胞瘤(GBM)患者中的疗效。40 名符合条件的患者在第 1 天接受卡铂(AUC 为 4mg/ml-min),而贝伐珠单抗(CYP3A 酶诱导性抗癫痫药 [EIAED] 患者为 10mg/kg,非 EIAED 患者为 125mg/m2)在每个 28 天周期的第 1 天和第 14 天给药。在每两个周期的第一次评估后以及之后每隔一个周期评估患者。治疗继续进行,直到疾病进展、不可接受的毒性、不遵医嘱或自愿退出。主要终点是 6 个月无进展生存期(PFS-6),次要终点包括安全性和中位总生存期(OS)。所有患者在标准治疗后均有进展。中位年龄为 51 岁。16 名患者(40%)的 KPS 为 90-100,而 27 名患者(68%)为首次进展。从最初诊断到中位时间为 11.4 个月。PFS-6 率为 46.5%(95%CI:30.4,61.0%),中位 OS 为 8.3 个月[95%置信区间(CI):5.9,10.7 个月]。4 级事件主要为血液学事件,包括中性粒细胞减少症和血小板减少症,分别占 20%和 10%。最常见的 3 级事件为中性粒细胞减少症、血小板减少症、疲劳和感染,分别占 25%、20%、13%和 10%。11 名患者(28%)因毒性而停止研究治疗,17 名患者(43%)需要剂量调整。1 名患者因治疗相关肠穿孔而死亡。卡铂和伊立替康联合贝伐珠单抗显著增加了毒性,但在贝伐珠单抗初治复发性 GBM 患者中,并未提高抗肿瘤活性,与单药贝伐珠单抗的历史疗效相当。(临床试验.gov 编号 NCT00953121)。